Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT01192399 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29
Last updated 2018-03-13
Summary
A study to assess the safety and efficacy of eculizumab in Japanese patients with hemolytic PNH.
Conditions
Interventions
- BIOLOGICAL
Sponsors & Collaborators
-
Alexion Pharmaceuticals, Inc.
lead INDUSTRY
Principal Investigators
-
Stephen Squinto, PhD · Alexion Pharmaceuticals, Inc.
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-11-30
- Primary Completion
- 2008-06-30
- Completion
- 2008-06-30
- FDA Drug
- Yes
More Related Trials
-
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
NCT06449001 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04901936 ·Status: RECRUITING ·Phase: PHASE2
-
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
NCT03078582 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
NCT00275613 ·Status: COMPLETED ·Phase: PHASE1
-
An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN
NCT06987864 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
NCT03593200 ·Status: COMPLETED ·Phase: PHASE2
-
Ruxolitinib Combined With Dexamethasone for HLH
NCT03795909 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
NCT03759366 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
NCT05133531 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy of INM004 in Children With STEC-HUS
NCT06389474 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood
NCT01268033 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT05131204 ·Status: TERMINATED ·Phase: PHASE3
-
Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
NCT05491304 ·Status: RECRUITING ·Phase: PHASE4
-
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab
NCT03030183 ·Status: COMPLETED ·Phase: PHASE2
-
Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
NCT03427060 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
NCT06951971 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
NCT06339177 ·Status: RECRUITING
-
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
NCT01573533 ·Status: COMPLETED ·Phase: PHASE2
-
Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
NCT04120090 ·Status: UNKNOWN ·Phase: PHASE3
-
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
NCT04551131 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Therapy of Chronic Cold Agglutinin Disease With Eculizumab
NCT01303952 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria
NCT04058158 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
NCT05067127 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
NCT02477332 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
NCT03616184 ·Status: COMPLETED ·Phase: PHASE2